Erectile dysfunction and coronary artery disease in patients with diabetes

Current Diabetes Reviews

Volumn 7, Issue 2, 2011, Pages 143-147

  Gazzaruso, Carmine ^a   Coppola, Adriana ^a   Giustina, Andrea ^b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Coronary artery disease; Diabetes; Erectile dysfunction; Silent myocardial ischemia

Indexed keywords

METFORMIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; DIABETIC PATIENT; DIET THERAPY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOGONADISM; HYPOTHYROIDISM; INJURY; LIFESTYLE MODIFICATION; MALE; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SMOKING CESSATION; SPINAL CORD INJURY; WEIGHT REDUCTION; ADULT; AGED; COMPLICATION; DIABETES COMPLICATIONS; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADULT; AGED; CORONARY DISEASE; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED;

EID: 79953022760     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794940693     Document Type: Review

References (49)

1. Gazzaruso C. Erectile dysfunction and silent myocardial ischemia. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J eds. Harrison's Principles of Internal Medicine, 16th ed. New York, NY: McGraw Hill Medical 1/13/2005 update online.
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-6.
3. Feldman HA, Goldstein I, Hatzchristou DG, et al. Impotence and its medical and psychosocial correlates: results from the Massachusetts male aging study. J Urol 1994; 151: 54-61.
4. Fedele D, Bortolotti A, Coscelli C, et al. Erectile dysfunction in type 1 and type 2 diabetics in Italy. Int J Epidemiol 2000; 29: 524- 31.
5. Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med 2007; 74: S30-S7.
6. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-4.
7. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002.
8. Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20: 92-9.
9. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108-13.
10. Chew KK, Finn J, Stuckey B, et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med 2010; 7: 192-202.
11. Bohm M, Baumhakel M, Teo K, et al.; for the ONTARGET/ TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile Dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET)/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trials. Circulation 2010; 121: 1439-46.
12. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction linkes erectile dysfunction to heart disease. Int J Clin Pract 2005; 59: 225- 9.
13. Cheitlin MD. Erectile dysfunction: the earliest sign of generalized vascular disease? J Am Coll Cardiol 2004; 43: 185-6.
14. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involment: the COBRA trial. Eur Heart J 2006; 27: 2632-9.
15. Cameron NE, Cotter MA. Erectile dysfunction and diabetes mellitus: mechanistic considerations from studies in experimental models. Curr Diabetes Rev 2007; 3: 149-58.
16. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular diseases in diabetes. Diabetologia 2001; 44: S14-S21.
17. Gazzaruso C, Pujia A, Solerte SB, et al. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int J Impot Res 2006; 18: 311-5.
18. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-6.
19. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with asymptomatic coronary artery disease angiographically proven. A potential protective role for statins and 5- phosphodiesterase inhibitors. J Am Coll Cardiol 2008; 51: 2040-44.
20. Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronaryartery disease in type 2 diabetes. J Am Coll Cardiol 2008; 51:2045-50.
21. Batty GD, Qiang L, Czernichow S, et al. on behalf of the ADVANCE Collaborative Group. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes. J Am Coll Cardiol 2010; 56: 1908-13.
22. Gazzaruso C, Coppola A, Montalcini T, et al. Screening for asymptomatic coronary artery disease can reduce mortality and morbidity in type 2 diabetic patients. Int Emerg Med 2011, DOI: 10.1007/s11739-011-0527-5.
23. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22-6.
24. Chiurlia E, D'Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005; 46: 1503-6.
25. Vlachopoulos C, Rokkas K, Ioakeimidis N, et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol 2005; 48: 996-1002.
26. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010; 64: 848- 57.
27. Stern S. Symptoms other than chest pain may be important in the diagnosis of "silent ischemia", or "the sounds of silence". Circulation 2005; 111: e435-e7.
28. Lee HL, Ngengwe R, Jones P, Tang F, O'Keefe JH. Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol 2008; 15: 800-3.
29. Rosen RC. Evaluation of the patient with erectile dysfunction: history, questionnaires, and physical examination. Endocrine 2004; 23: 107-11.
30. Kloner R, Padma-Nathan H. Erectile dysfunction and coronary artery disease. Int J Impot Res 2005; 17: 209-15.
31. Bruzziches R, Greco EA, Pili M, Francomano D, Spera G, Aversa A. Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. Curr Diaberes Rev 2008; 4: 24-30.
32. Fink HA, MacDonald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349-60.
33. Miner MM, Seftel AD. Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's health and do they improve traditional non-gender specific determinants to lessen cardiovascular risk and all-cause mortality? In J Clin Pract 2010; 64: 1754-62.
34. Gazzaruso C. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. Expert Rev Cardiovasc Ther 2006; 4: 173-80.
35. Giugliano F, Maiorino M, Bellastella G, Gicchino M, Giugliano D, Esposito K. Determinants of erectile dysfunction in type 2 diabetes. Int J Impot Res 2010; 22: 204-9.
36. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol 2005; 96: 313-21.
37. Adeniyi AF, Adeleye AO, Adeniyi CY. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. Curr Diabetes Rev 2010; 6: 201-6.
38. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for Therapy. J Clin Hypertens 2002; 4: 424-32.
39. Toblli J, Stella I, Nestor Mazza O, et al. Protection of cavernous tissue in male spontaneously hypertensive rats. Beyond blood pressure control. Am J Hypertens 2004; 17: 516-22.
40. Park K, Shin JW, Oh JK, et al. Restoration of erectile dysfunction capacity in normatensive aged rats by modulation of angiotensin receptor type 1. J Androl 2005; 26: 123-8.
41. Cordero A, Bertomeu-Martivez V, Mazon P, et al. Erectile dysfunction in high rish hypertensive patients treated with betablockade agents. Cardiovasc Ther 2010; 28: 15-22.
42. Baumkakel M, Schlimmer N, Buyukafsar K, Arikan O, Bohm O. Nevivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein-e knoutout mice. J Pharmacol Exp Ther 2008; 325: 818-23.
43. Cheitlin MD. Should the patient with coronary artery disease use sildenafil? Prev Cardiol 2003; 6: 161-5.
44. Weinsaft JW, Hickey K, Bokhari S, et al. Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. Coron Artery Dis 2006; 17: 493-9.
45. Reffelmann T, Kloner RA. Cardiovascular effects of phospodiesterase 5 inhibitors. Curr Pharm Des 2006; 12: 3485-94.
46. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase 5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007; 19: 55-61.
47. Bocchio M, Pelliccione F, Passaquale G, et al. Inhibition of hosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis 2008; 196: 313-9.
48. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-40.
49. Kloner RA. Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient. Endocrine 2004; 23: 125-9.